← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation
tenapanor
A06AX08
Adult Dosing
- Irritable Bowel Syndrome with Constipation (IBS-C): 50 mg orally twice daily, immediately before breakfast/first meal of the day and immediately before dinner
- Hyperphosphatemia in Chronic Kidney Disease (CKD): 50 mg orally twice daily, immediately before breakfast and dinner
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of irritable bowel syndrome with constipation (IBS-C) in adults
- Reduction of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis
Mechanism of Action
- Locally acting inhibitor of the sodium-hydrogen exchanger 3 (NHE3) in the gastrointestinal tract
- Inhibition of NHE3 reduces sodium and water absorption, increasing intestinal transit and stool water content (IBS-C indication)
- Inhibition of NHE3 blocks passive paracellular absorption of dietary phosphate, reducing serum phosphorus levels (CKD indication)
Contraindications
- Known or suspected mechanical gastrointestinal obstruction
- Patients less than 6 years of age due to the risk of severe dehydration
- Known hypersensitivity to tenapanor or any of its components
Adverse Reactions
- Diarrhea (most common, can be severe)
- Abdominal distension
- Flatulence
- Abdominal pain
- Dizziness
Drug Interactions
- No clinically significant pharmacokinetic drug-drug interactions identified based on in vitro and in vivo studies
- May potentially decrease the absorption of concurrently administered oral medications due to accelerated gastrointestinal transit (monitor clinical efficacy)
Curated Content: Needs Vetting Before Put to Clinical Use